Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process

NCT00169494 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00169494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00169494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
July 31, 2005
Enrollment
770 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

infections, papillomavirus